Business Information Report

WUXI BIOLOGICS CO., LTD

Chinese Name	*无锡药明生物技术股份有限公司*
Previous Name(s)	Wuxi Yaoming Kangde Biotechnology Co., Ltd (Date of Name Change : 30-Oct-2018)
Previous Name(s)	Wuxi Yaoming Kangde Biotechnology Co., Ltd (Date of Name Change : 10-Jun-2015)
Regd./Business Address	No. 108, Meiliiang Road, Mashan, Binhu Dist, Jiangsu Province, Wuxi City - 214092, China
Phone	+86 18168857700
Phone	+86 51081831376
Email	IR@wuxibiologics.com
Website	www.wuxibiologics.com.cn
Comments	Premises use for Production, Office

Executive Summary

Report ID	674255
Entity Name	Wuxi Biologics Co., Ltd
Company Status	Active
Operating Status	Active
Legal Form	Joint Stock Company
Regd./Formation Date	25 May 2010
Business Type	Manufacturer
Unified Social Credit Code	91320200553816325A
No. of Employees	3060+

Financial Summary

Net Worth	CNY	21,392,603,000
Total Revenue	CNY	5,537,713,000
Profit Before Tax	CNY	2,179,717,000
FY Ended	31-Dec-2024	

Business Activity	Production of biological medicine
Shareholding Details	China Nationals (55.00%); Hong Kong Nationals (45.00%)
SIC Code(s)	2441 - Manufacture of basic pharmaceuticals
	2442 - Manufacture of pharmaceutical preparations
	5146 - Wholesale of pharmaceutical goods
NACE Code(s)	2110 - Manufacture of basic pharmaceutical products
	2120 - Manufacture of pharmaceutical preparations

Business Information Report

Notes	* The complete and correct name and address of the subject is mentioned above. * License details have been procured from local registry.

Company Identifiers

1. Unified Social Credit Code	91320200553816325A
Registry	Wuxi Municipal Administration for Market Regulation
2. AIC Registration No.	320200400034305
3. National Organization Code	553816325

Credit Recommendation

Credit Rating	B
Credit Score	60
Credit Limit	USD 1000000
Comments	Recommendation is largely based on the operational details, longevity and available financial extracts of the subject. However, conservative as the subject has witnessed a decline in its turnover and profit levels.

Credit Rating Guide

Credit Rating	Credit Score	Explanation
A+	81 - 100	Low Risk
A	61 - 80	Moderate Risk
B	40 - 60	Medium Risk
C	21 - 39	Medium High Risk
D	1 - 20	High Risk
NR	--	No Rating

Capital Structure / Ownership

Authorised Capital CNY 8 915 770 000

Shareholding Structure / Major Shareholder(s)

Name	Holding (%)	Country of Origin
Wuxi Yaoming Enterprise Management Co. Ltd.	55.00	China
WuXi Biologics Investments Limited	45.00	Hong Kong
TOTAL	**100.00**	

Business Information Report

Background of Shareholder(s)

1	**Name**	Wuxi Yaoming Enterprise Management Co. Ltd.
	Address	No. 108 Meiliang Road, Mashan, Binhu District, Wuxi City, China
	National ID	Unified Social Credit Code: 91320200312248291G

Directors / Principals

1	**Name**	Chen Zhisheng
	Designation	Chairman
2	**Name**	Guo Wei
	Designation	Director
3	**Name**	Tu Xiaoming
	Designation	Director

Key Personnel

1	**Name**	Chen Zhisheng
	Designation	Manager
2	**Name**	Li Li
	Designation	Supervisor
3	**Name**	Wang He
	Designation	Supervisor
4	**Name**	Huang Ke
	Designation	Supervisor

Business Operations

The subject company is engaged in production of biological medicine.

Business Scope

Licensed projects: pharmaceutical production; pharmaceutical entrusted production; pharmaceutical import and export; construction engineering design; inspection and testing services (projects that require approval according to law can only be carried out after approval by relevant departments, and specific business projects are subject to the approval results) General projects: engineering and technology research and test development; engineering technical services services (except planning management, survey, design, and supervision); engineering management services; certification consulting; standardization services; information consulting services (excluding licensing information consulting services); technical services, technology development, technical consulting, technical exchanges, technology transfer, and technology promotion; pharmaceutical special equipment manufacturing; medical packaging materials Manufacturing; sales of packaging materials and products; packaging

	services; sales of synthetic materials; sales of plastic products; sales of chemical products (excluding licensed chemical products); general cargo warehousing services (excluding hazardous chemicals and other items requiring license approval); low-temperature warehousing (excluding hazardous chemicals and other items requiring license approval); transportation Packaging services for transportation; loading and unloading; sales of Class I medical devices; import and export of goods; medical research and experimental development (except for the development and application of human stem cells, genetic diagnosis and treatment technologies); engaging in investment activities with own funds (except for projects that require approval according to law, independently carry out business activities with a business license in accordance with the law)
Products & Service	Subject is an enterprise mainly engaged in pharmaceutical research, production and marketing. Subject's business involves the research and development and production of chemical drugs, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production, etc. Products include: Proteins Plasmid DNA Viral vector products Immune drugs Enzyme products
Customer Type	Pharmaceutical manufacturing enterprises, pharmaceutical distributor, etc.
Qualifications & Trends	Trademarks:55 Patent:106 Copyright:0
Certifications	Certificate type: Information security management system certification Expiry date: Jan-27-2028 Certificate no.: IS762433 Status : Valid Issuing authority : British Standard Management System Certification (Beijing) Co., Ltd.
Administrative Licensing	Licensed document code: S 20160503 License file name: Drug production license Operation starting date: Jun-22-2026 Operation expiry date: Dec-19-2030 Licensing authority: Jiangsu Provincial Food and Drug Administration
Land Purchase Information	Announcement of land transfer result: Entry name: The plot on the northwest side of the intersection of Shuichan Road and Meiliang Road Land location: Northwest side of the intersection of Shuichan Road and Meiliang

	Road, Mashan Subdistrict, Binhu District, Wuxi City Area (HA): 6.35 Land user: Wuxi Biologics Co., Ltd Land use: Industrial land Transaction price (10000 yuan): -- Contract Signing Date : Feb.15,2019 Publish time: --
Imports From	U.S.A, Sweden, France, etc.
Exports To	U.S.A, The United Kingdom, Switzerland, etc.
Payment Terms	Domestic: Prepayment, prompt payment, etc. (Sale) International: Letter of Credit, Telegraphic Transfer (Sale) Domestic: Prompt payment, payment as agreed, etc. (Purchase) International: Letter of Credit, Telegraphic Transfer (Purchase)
Sales	International - 5% Domestic - 95%
Purchase	International - 25% Domestic - 75%
Listing on Stock Exchange	No
Litigation	Hearing Court : Shanghai Pudong New District People`s Court Case Cause : Partnership disputes Party : Plaintiff: Ningbo Menohua Ruihe Equity Investment Partnership (Limited Partnership) : Defendant: Fukang (Shanghai) Health Technology Co., Ltd. Third Party: Shen Xiaokun, Luochang (Shanghai) Enterprise Management Center (Limited Partnership), Zhonghe (Shanghai) Biotechnology Co., Ltd., Wuhan Haihui Equity Investment Fund Partnership (Limited Partnership), Wuxi Biologics Co., Ltd., Huang Suling, Gao Yanwen Case No. : (2021) H 0115 MC 48158 Closing Date : Jun.23,2021 Case status : Civil first instance Document Type : Civil case Judge Result : The ruling is as follows: The plaintiff Ningbo Menohua Ruihe Equity Investment Partnership (Limited Partnership) is allowed to withdraw the lawsuit. The case acceptance fee is CNY 80, half of which is CNY 40, which will be borne by the plaintiff Ningbo Menohua Ruihe Equity Investment Partnership (Limited Partnership). Hearing Court : Beijing Intellectual Property Court Case Cause : Intellectual property disputes Party : Plaintiff: Wuxi Biologics Co., Ltd Defendant: State Intellectual Property Office Case No. : (2019) J 73 XC 9280 Closing Date : Sept.03,2019

Case status : Administrative first instance
Document Type : Administrative cases
Judge Result : The judgment is as follows:
The lawsuit filed by the plaintiff Wuxi Biologics Co., Ltd. is dismissed. The case acceptance fee of one hundred CNY shall be borne by the plaintiff Wuxi Biologics Co., Ltd. (already paid).
If they are not satisfied with this judgment, both parties may submit an appeal and a copy to this court within 15 days from the date of delivery of this judgment, and pay the appeal case acceptance fee of 100 yuan to appeal to the Beijing Higher People`s Court.

Subject has 2 court session announcement records. :
Area: Beijing City
Court: Beijing Intellectual Property Court
Case No.: （2019）J 73 XC 9280
Content: This court is scheduled to hold a public hearing in this court on Aug.13, 2019. The plaintiff: Wuxi Biologics Co., Ltd.; the defendant: the State Intellectual Property Office; and one other case.

Area: Binhu District, Wuxi City, Jiangsu Province
Court: Binhu District People`s Court of Wuxi City, Jiangsu Province
Case No.: （2018）S 0211 MC 2686
Content: This court is scheduled to hold a public hearing in this court at 09:30:00 on Jun.06,2018. The plaintiff: Shanghai Taiyi Culture Communication Co., Ltd.; the defendant: WuXi AppTec Enterprise Management Co., Ltd.; copyright ownership dispute case.

Negative Database Check

OFAC Search	No matches found
UN Sanction List	No matches found
EU Sanction List	No matches found
UK Sanction List	No matches found

Previous Address

Address:	No. 88, Meiliang West Road, Mashan, Binhu District, Wuxi City, China
Date of Change:	23-Jun-2017

Affiliates/Associates

Subsidiary

Name	Wuxi Yuankang Investment Management Co. Ltd.
Remarks	Unified Social Credit Code: 91320211MA231GCQ1T License Status: Operational Date of Establishment: 10-11-2020 Registered Capital: CNY 2,500,000,000.00
Holding (%)	100.00
Name	Wuxi Biologics (Shanghai) Co. Ltd.
Remarks	Unified Social Credit Code: 913101153243267 95T License Status: Operational Date of Establishment: 06-01-2015 Registered Capital: CNY 1,330,000,000.00 Operating Income: 4.4 - 4.9B
Holding (%)	100.00
Name	Suzhou Yaoming Testing Co. Ltd.
Remarks	Unified Social Credit Code: 913205065969693133 License Status: Operational Date of Establishment: 30-05-2012 Registered Capital: CNY 42,860,000.00 Operating Income: 800-900M
Holding (%)	100.00
Name	Beijing Yaoming Biological Technology Co. Ltd.
Remarks	Unified Social Credit Code: 91110105MA01W14L23 License Status: Operational Date of Establishment: 18-09-2020 Registered Capital: CNY 30,000,000.00 Operating Income: 7-9M
Holding (%)	100.00
Name	Shanghai Yaoming Testing Co. Ltd.
Remarks	Unified Social Credit Code: 91310000MA1H3YWK0K License Status: Operational Date of Establishment: 22-07-2021 Registered Capital: CNY 100,000,000.00 Operating Income: 1.7-2.7M
Holding (%)	75.00
Name	Hebei Yaoming Biotechnology Co. Ltd.
Remarks	Unified Social Credit Code: 91130100MA0CETRA74 License Status: Operational Date of Establishment: 19-06-2018 Registered Capital: USD 62,000,000.00 Operating Income: 200-300M
Holding (%)	75.00

Business Information Report

Name	Hangzhou Mingde Biomedical Technology Co. Ltd.
Remarks	Unified Social Credit Code: 91330100MA2GY6779G License Status: Operational Date of Establishment: 16-09-2019 Registered Capital: USD 110,000,000.00 Operating Income: 100-200M
Holding (%)	55.00

Name	Hangzhou Mingde Biological New Technology Development Co. Ltd.
Remarks	Unified Social Credit Code: 91330100MA2HX5384Y License Status: Operational Date of Establishment: 30-04-2020 Registered Capital: USD 20,000,000.00 Operating Income: 200-300M
Holding (%)	55.00

Name	Bestchrom (Shanghai) Biosciences Ltd
Remarks	Unified Social Credit Code: 913101156762082904 License Status: Operational Date of Establishment: 01-07-2008 Registered Capital: USD 150,000.00 Operating Income: 200-300M
Holding (%)	50.10

Name	Chengdu Yaoming Biotechnology Co. Ltd.
Remarks	Unified Social Credit Code: 91510115MA6C7CML19 License Status: Operational Date of Establishment: 04-12-2017 Registered Capital: USD 120,000,000.00 Operating Income: 70-90M
Holding (%)	50.00

Name	WuXi Biologics (Chengdu) Co. Ltd.
Remarks	Registered Capital: USD 120,000,000
Holding (%)	50.00

Banker

Name	Agricultural Bank of China Limited
Address	Wuxi Lingshan Sub-branch
Account No	CNY 658001040009162

Business Information Report

FINANCIAL SUMMARY

NET WORTH — CNY in 000

Year Ended	Amount	Change
31-Dec-2024	21 392 603	12.35%
31-Dec-2023	19 040 478	19.17%
31-Dec-2022	15 977 015	--



TOTAL INCOME — CNY in 000

Year Ended	Amount	Change
31-Dec-2024	5 537 713	-14.26%
31-Dec-2023	6 458 774	-6.15%
31-Dec-2022	6 881 792	--



PROFIT BEFORE TAX — CNY in 000

Year Ended	Amount	Change
31-Dec-2024	2 179 717	-11.88%
31-Dec-2023	2 473 696	-11.18%
31-Dec-2022	2 785 020	--



PROFIT AFTER TAX — CNY in 000

Year Ended	Amount	Change
31-Dec-2024	1 927 198	-19.26%
31-Dec-2023	2 386 792	-9.10%
31-Dec-2022	2 625 633	--



Business Information Report

INCOME STATEMENT EXTRACTS

	31-Dec-2024	31-Dec-2023	31-Dec-2022
		(CNY in 000)	
Period	12 months	12 months	12 months
Source	Others	Others	Others
Type of Financials	Standalone	Standalone	Standalone
Operating Income	5 537 713.00	6 458 774.00	6 881 792.00
Total Profit	2 179 717.00	2 473 696.00	2 785 020.00
Income Tax	---	86 904.00	159 387.00
Net Profit	1 927 198.00	2 386 792.00	2 625 633.00

BALANCE SHEET EXTRACTS

	31-Dec-2024	31-Dec-2023	31-Dec-2022
		(CNY in 000)	
Period	12 months	12 months	12 months
Source	Others	Others	Others
Type of Financials	Standalone	Standalone	Standalone
Total Assets	22 240 029.00	20 470 868.00	17 865 966.00
Total Liabilities	847 426.00	1 430 390.00	1 888 951.00
Total Owner’s Equity	21 392 603.00	19 040 478.00	15 977 015.00
Total Liabilities and Owner's Equity	22 240 029.00	20 470 868.00	17 865 966.00

COMMENTS

* In view of the current imperfection of domestic information access channels, which may result in the omission of certain accounting items in the financial statements and the inconsistency between the accumulated amounts and the total amounts of some accounting items, this note is hereby given.

* Through official channels, we have only obtained the key financial information of Subject for 2023 and 2024 for Client`s reference.

TRADEMARKS

Name of Trademark	Number of Trademark	Status	Dedicated Due Date
MAGNICHO	72757999	Registered	Jan.13,2034
MAGNICHO	72756754	Registered	Jan.13,2034
MAGNICHO	72764811	Registered	Jan.13,2034
VECMASON	72259529	-Registered	Dec.27,2033
WUXILIAB	71480195	Registered	Nov.06,2033
HANDIPLASMID	67746368	Registered	Jun.27,2033
WUXILIAB	67701277	Registered	Jun.27,2033
DNASSEMBLER	67675918	Registered	May.13,2033
HANDIPLASMID	67746722	Registered	May.06,2033
VECMASON	67735595	Registered	May.06,2033

Business Information Report

PATENTS

Name	Application date	Type of Patents	Announcement No.	Status
Processing method, device, electronic equipment and storage medium for a process chain prediction model	Dec.26,2024	Invention notice	CN122290776A	Announce
Methods, devices, equipment and media for determining metabolite concentrations in cell culture fluids	Oct.17,2024	Invention notice	CN122270674A	Announce
A method, device, storage medium, and electronic apparatus for predicting CO2 information in a bioreactor	Nov.29,2024	Invention notice	CN122117102A	Announce
Automated report generation platform	Jan.15,2026	Invention notice	CN121981095A	Announce
A sugar control method to balance lactic acid and intact sugar chain antibody production and its application	Jan.08,2026	Invention notice	CN121874293A	Effectiveness of substantive examination
A method for rapid preparation of host cell DNA	Dec.31,2025	Invention notice	CN121852365A	Effectiveness of substantive examination
A method for determining the residual DNA content of HEK293 host cells	Jan.08,2026	Invention notice	CN121826121A	Effectiveness of substantive examination

Equipment for emulsion preparation and emulsion preparation method using the same	Dec.25,2025	Invention notice	CN121755100A	Effectiveness of substantive examination
Steam sampler	Feb.12,2025	practical	CN224019408U	Authorize
A method for reducing acidic charge variants of antibodies in mammalian cell culture and applications thereof	Dec.30,2025	Invention notice	CN121699846A	Effectiveness of substantive examination

Economic Outlook -China

	2022	2023	2024
GDP (Nominal)	$18307.82 Billion	$18270.35 Billion	$18749.76 Billion
GDP (Nominal) Growth %	3.10%	5.40%	5.00%
Inflation	1.97%	0.23%	0.22%
Un-Employment Rate %	4.98%	4.67%	4.57%

Population (2025 Estimated)	1,416,096,094
Density (2025 Estimated)	151 peoples / sq. km
Population Growth rate (2025 Estimated)	-0.23%
Life expectancy at birth (2025 Estimated)	77.81 Years
Sex Ratio (2025 Estimated)	1.04 male(s)/female

Imports From (2024)	Exports to (2024)
South Korea $181.50 Billion	United States $525.65 Billion
United States $164.59 Billion	Hong Kong $290.87 Billion
Japan $156.24 Billion	Vietnam $161.85 Billion
Australia $140.79 Billion	Japan $152.01 Billion
Russia $129.88 Billion	South Korea $146.23 Billion

Major Imports in 2024	Major Exports in 2024
Electrical, electronic equipment $583.88 Billion	Electrical, electronic equipment $927.09 Billion
Mineral fuels, oils, distillation products $504.02 Billion	Machinery, nuclear reactors, boilers $568.09 Billion
Ores slag and ash $251.06 Billion	Vehicles other than railway, tramway $215.98 Billion
Machinery, nuclear reactors, boilers $229.11 Billion	Plastics $141.16 Billion
Pearls, precious stones, metals, coins $118.88 Billion	Furniture, lighting signs, prefabricated buildings $126.29 Billion

Major Sectors (2024)	GVA (current US$)	Share % of GDP
Agriculture, forestry, and fishing	$1,270.08 Billion	6.78%
Services	$10,636.80 Billion	56.75%
Industry (including construction)	$6,836.93 Billion	36.48%

	2023	2024
Budget Deficit in %	-5.80%	-6.50%
Average Exchange Rate (USD to CNY)	7.08	7.18

* In the long-term, the China GDP is projected to trend around 20508.00 USD Billion in 2027 and 21431.00 USD Billion in 2028, according to econometric models.

* In the long-term, the China Consumer Price Index (CPI) is projected to trend around 105.78 points in 2027 and 106.84 points in 2028, according to econometric models.

* In the long-term, the China Inflation Rate is projected to trend around 0.80 percent in 2027 and 1.00 percent in 2028, according to econometric models.

* In the long-term, the China Government Budget is projected to trend around -4.00 percent of GDP in 2026 and -6.00 percent of GDP in 2027, according to econometric models.

Sources:
https://www.theglobaleconomy.com
https://www.exchange-rates.org
https://statisticstimes.com
https://www.worldometers.info
https://www.macrotrends.net
https://data.worldbank.org
https://tradingeconomics.com
https://oec.world

Business Information Report

Credit Rating Explanation

Credit Rating	Credit Score	Explanation	Rating Comments
A+	81 - 100	Low Risk	Business dealings permissible with low risk of default.
A	61 - 80	Moderate Risk	Business dealings permissible with moderate risk of default.
B	40 - 60	Medium Risk	Business dealings permissible on a regular monitoring basis.
C	21 - 39	Medium High Risk	Business dealings permissible preferably on secured terms.
D	1 - 20	High Risk	Business dealing not recommended or on secured terms only.
NR	--	No Rating	No recommendations can be made at this stage due to lack of sufficient information.

The credit appraisal provides an assessment of the creditworthiness of a company. It takes into account significant elements of credit including history, business performance, management, background, financial position, payment history, overall market conditions, market trends and the reputation of the company

NR is stated where there is insufficient information to facilitate rating. However, it is not to be construed as unfavorable.

This report is based on information from sources believed to be true. Any advice or recommendation in this report has been given without specific investment objectives and the particular needs of any specific addressee. It must be distinctly understood that though utmost care has been exercised to obtain reports of a reliable character but we accept no liability whatsoever for any direct or consequential loss arising from any use of this document.

END OF REPORT